Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Predominantly Demyelinating Neuropathy With or Without Anti-MAG
Latest Information Update: 26 Apr 2025
At a glance
- Drugs Acalabrutinib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Paraproteinaemia; Peripheral neuropathies; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
Most Recent Events
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Apr 2022 Trial design presented at the 113th Annual Meeting of the American Association for Cancer Research
- 22 Nov 2021 Planned primary completion date changed from 1 Oct 2026 to 1 Dec 2026.